


Financial Factsheet

Q2 2025


01.01.2025 – 31.03.2025

GROUP


Revenue-Bridge (EURm)



Revenues by region (EURm)



Revenues by segment (EURm)



Results (EURm)

	Q2 2025	Q2 2024
Revenues	252	234
EBITDA	72	44
EBITDA margin	28.6%	18.9%
EBITDA margin (at constant currencies)	28.2%	27.1%
EBIT	53	28
EBIT margin	21.0%	12.2%
Financial result	-3	-2
Income tax expense	-11	-1
Profit for the period	39	25
EPS (in EUR)	0.26	0.17

Financial position (EURm)

	Q2 2025	Q2 2024
Cash flow from operating activities (A)	48	25
Cash flow from investing activities (B)	-29	-29
Free cash flow (A+B)	19	-3

Net assets (EURm)

	31.3.2025	30.9.2024
Working Capital	204	175
Working Capital ratio to revenues	21.0%	18.3%
Equity ratio	56.2%	54.9%
Net debt	113	119


Employees

	31.3.2025	30.9.2024
Headcount	4,790	4,690

DRUG CONTAINMENT SOLUTIONS

(DCS)*

Revenue-Bridge (EURm)




Results (EURm)

	Q2 2025	Q2 2024
EBITDA	33	28
EBITDA margin	23.3%	20.6%
EBIT	24	19
EBIT margin	16.8%	14.0%

DRUG DELIVERY SYSTEM

(DDS)*

Revenue-Bridge (EURm)



Results (EURm)

	Q2 2025	Q2 2024
EBITDA	38	39
EBITDA margin	34.4%	38.4%
EBIT	28	32
EBIT margin	25.7%	31.6%